Obesity is a prevalent health issue that affects people of all ages at a high rate. Tirzepatide (TZP) is a hypoglycemic medication that acts as a dual antagonist for both the GIP-1 and GIP receptors. Previous reports have shown that TZP treatment demonstrated substantial weight reduction as well as lipid-modulating effects in obese and overweight individuals.
No takes yet. Share an insight, caveat, or question.
Alathary et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: